These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 16414486)

  • 1. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F; McKiernan J; Eastham J
    Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
    Saad F
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
    Saad F; Abrahamsson PA; Miller K
    BJU Int; 2009 Dec; 104(11):1573-9. PubMed ID: 20053188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for treatment and prevention of bone metastases.
    Michaelson MD; Smith MR
    J Clin Oncol; 2005 Nov; 23(32):8219-24. PubMed ID: 16278476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.
    Saad F; Higano CS; Sartor O; Colombel M; Murray R; Mason MD; Tubaro A; Schulman C
    Clin Genitourin Cancer; 2006 Mar; 4(4):257-62. PubMed ID: 16729908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
    Green JR
    Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
    Polascik TJ; Given RW; Metzger C; Julian SR; Vestal JC; Karlin GS; Barkley CS; Bilhartz DL; McWhorter LT; Lacerna LV
    Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintaining bone health in prostate cancer throughout the disease continuum.
    Saad F; Eastham J
    Semin Oncol; 2010 Jun; 37 Suppl 1():S30-7. PubMed ID: 20682370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
    Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
    BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy.
    Saad F; Sternberg CN
    Nat Clin Pract Urol; 2007 Feb; 4 Suppl 1():S3-13. PubMed ID: 17264863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    Ryan CW; Huo D; Demers LM; Beer TM; Lacerna LV
    J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preservation of bone health in prostate cancer.
    Lattouf JB; Saad F
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
    Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history and treatment of bone complications in prostate cancer.
    Saad F; Clarke N; Colombel M
    Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care.
    Saad F; Olsson C; Schulman CC
    Eur Urol; 2004 Dec; 46(6):731-39; discussion 739-40. PubMed ID: 15548440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.